Cost-effectiveness of rotavirus vaccination in Turkey

Basit Öğe Kaydı
dc.authoridAkelma, Zulfikar/0000-0003-0140-5053;
dc.contributor.authorKoksal, Tulin
dc.contributor.authorAkelma, Ahmet Zulfikar
dc.contributor.authorKoksal, Ali Osman
dc.contributor.authorKutukoglu, Irem
dc.contributor.authorOzdemir, Osman
dc.contributor.authorYuksel, Cigdem Nuket
dc.contributor.authorBozkaya, Davut
dc.date.accessioned2025-10-24T18:09:05Z
dc.date.available2025-10-24T18:09:05Z
dc.date.issued2017
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground/Purpose: Cost-effectiveness studies about rotavirus (RV) vaccination programs were performed in many countries due to the severe economic burden of RV infections. This study is an economic evaluation performed to assess the potential for introducing the RV vaccine to the Turkish National Immunization Program. Methods: In this retrospective clinical study, the records and laboratory findings of a total of 4126 patients admitted to Turgut Ozal University Hospital, Ankara, Turkey with acute gastroenteritis were analyzed. A model described by Parashar et al. was used to obtain the annual episodes of diarrhea, hospitalization and outpatients visits in Turkey. Monovalent and pentavalent vaccination was assumed to protect in average 85% of RV acute gastroenteritis. All costs are expressed in 2012 United States (US) $, where US$1 equals 1.8 Turkish Liras (TL). Losses of labor costs were not taken into consideration. Results: The vaccination program with 85% coverage was cost effective and cost saving compared to no vaccination. A projected birth cohort of 1.25 million children was followed until 5 years of age; a routine vaccination could potentially avert 210,994 cases of diarrhea treated in outpatient hospital facilities and 42,715 hospitalizations. The RV associated economic burden was obtained as US$17,909 million per year (US$14.33 per birth annually) in medical direct costs by using the national level of RV diarrhea disease burden estimates. For monovalent and pentavalent vaccination, assuming a cost of US$31.5 and US$38 per vaccine course, the cost of the vaccination program was estimated to be approximately US$37,878 million and US$45,475 million, respectively. Conclusion: At a cost per vaccine course of US$31.5 for monovalent and US$38 for pentavalent vaccine, routine RV vaccination could be potentially cost effective and also cost saving in Turkey. National RV vaccinations will play a significant role in preventing RV infections. Copyright (C) 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
dc.identifier.doi10.1016/j.jmii.2016.03.005
dc.identifier.endpage699
dc.identifier.issn1684-1182
dc.identifier.issn1995-9133
dc.identifier.issue5
dc.identifier.pmid27107612
dc.identifier.scopus2-s2.0-84963963348
dc.identifier.scopusqualityQ1
dc.identifier.startpage693
dc.identifier.urihttps://doi.org/10.1016/j.jmii.2016.03.005
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3459
dc.identifier.volume50
dc.identifier.wosWOS:000418084800019
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Taiwan
dc.relation.ispartofJournal Of Microbiology Immunology And Infection
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectcost effectiveness; gastroenteritis; hospitalized child; rotavirus; vaccination
dc.titleCost-effectiveness of rotavirus vaccination in Turkey
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu